rivaroxaban (Xarelto)


Original post, click here

Generic Name: rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Manufacturer Requested Reimbursement Criteria1:

​For use in combination with low-dose ASA, for the prevention of stroke, myocardial infarction and cardiovascular death in patients with concomitant coronary artery disease (CAD) or peripheral artery disease (PAD).

Submission Type: New Indication

Project Status: Pending

Call For Patient Input: April 25, 2018

Patient Input Closed: June 14, 2018

Anticipated Date: May 24, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Tags

coronary artery disease, stroke, cardiovascular, heart attack, peripheral vascular disease